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A B S T R A C T
The rise of pharmaceutical costs is a significant burden to overall health care expenditure. The Croatian Health In-
surance Fund (CHIF) in attempts of its containment, use administrative measures directed toward the two greatest gen-
erators: pharmaceutical industry, through negotiating prices and periodic revisions of basic and suplemental drug lists,
and primary care physicians, through limits in the volume of prescriptions, and annual financial expenditure. The aim
of the study was to determine trends in quantity of issued prescriptions and pharmaceutical expanditure from 2000 to
2012. Data were obtained from the CHIF annual reports. Results clearly demonstrate two trends: the increase in quantity
of issued prescriptions, together with accompanying rates: number of prescriptions per inhabitants, and per patients,
and the increase in total cost of prescriptions until 2004, with their maintenance and slight variations since then. Despite
controversies in approach, CHIF succeded in slowing down the costs, primarily by applying measures towards regula-
tion of drug prices.
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Introduction
The costs of health care increase worldwide at much
faster rate than income of health funds, with particularly
rapid growth of pharmaceutical expenses. In the Euro-
pean Union (EU) countries, public and private outpa-
tient spending on pharmaceuticals constitute around
16% of the total healthcare costs, or 1.6% of gross domes-
tic product (GDP)1,2. In most countries health insurance
institutions, in charge of supervision of pharmaceutical
costs, attempt, by various administrative and educa-
tional measures, to slow down (usually incessant) trend
of growth, while free pricing is almost completely aban-
doned.
The first and most important step in their control is
arbitrary setting of the highest price which health fund is
able to pay (refund), and which is done by external refer-
ence pricing, (ERP), internal reference pricing (IRP), as
well as health technology assessment projects, revisions
of positive drug lists, price reductions and »freezings«,
procurements through public tendering and other moda-
lities1,3.
The health system in Croatia constantly changes sin-
ce 1990-ies. Initially, the changes included organization
of health care and functionning of health institutions4,5.
Since 2006, the cluster of reforms was focused on de-
creasing the growth of expenses, particularly those of
prescription drugs. The main instrument in achieving
this goal, as well as being one of the pillars of health re-
form, was a positive listing system, consisting of basic
drug list (from 1991), and supplemental drug list (from
2004)6. Both of them included drug prices established
through external reference pricing, and performed by
Pharmaceutical Commitee of the Croatian Health Insur-
ance Fund (CHIF), following the Regulation on whole-
sale drug prices and Regulation for criteria on inclusion
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of drugs on basic and supplemental lists of the CHIF7,8.
Additionally, the period from 2001, especially after 2004,
was marked with the intense negotiations on price reduc-
tion between the state-run CHIF and representatives of
pharmaceutical industry9–14.
The second important cluster of measures was di-
rected toward primary health care (PHC) physicians, as
the only group inside the health system authorized in
prescibing of medicines. Family physicians (FP) are the
largest section and also the greatest prescribers, but
paediatricians, gyneacologists and stomatologists, ac-
counting for arround 20% of PHC teams, are also autho-
rized in prescibing of medicines. Restrictive precribing
rules in contracting with the CHIF applied to all of them.
There was, since 2003, a provision of average annual
quantity of prescription and referral forms (5 prescrip-
tion forms and 2 referral forms) per patients on the PHC
physician's list, which in 2006 increased to 8 prescription
forms15,16. In addition to the fixed number of prescription
forms, physicians were receiving them as quarterly sup-
plies, and, if overspent, requesting any extra number
from the local CHIF office together with an explanation.
These administrative regulations produced a great strain
to already overburdened PHC physicians, resulting in
feeling of frustration and lack of motivation for improve-
ments in quality of prescribing. A limit of annual finan-
cial spending was also introduced in 1998 – to around 254
Croatian kunas (HRK), or 33.5 EUR (1 EUR = 7.6 HRK,
according to exchange rate from 16.06.2014), per patient
on FP’s lists (508,200 HRK or 67,000 EUR, for the list of
2000 insurees, in 1998)17. Since 2003, CHIF introduced
rewarding of physicians who succeded in saving financial
means for prescription drugs throughout the year (with
up to 25% of saved money), as well as penalties for those
who overspent15. This strategy became soon inefficient,
because of rewarding mostly primary pediatricians, hav-
ing infants and pre-schoolers on their lists, against the
insignificant number of chronic patients. But penalties
for »big spenders« remained until now, although in dif-
ferent administrative form. In 2005 the annual limit sub-
stantially increased, from 365 HRK to 500 HRK (66
EUR) per patient on the FP's list, and also in 2009 to 665
HRK (87 EUR), staying on that approximate level until
today (680 HRK per insured person, or 90 EUR, in
2012)18–20. Repeated prescriptions were initiated only in
2009 (up to the period of six months) and since 2011 in
electronic form21. However, the administrative regula-
tion regarding obligatory use of generic drugs has never
been declared.
Patients’ participation in drug costs has also been
part of an effort to facilitate the sustainability of CHIF.
Co-payments, initiated from early 1990ies, has never
presented a financial burden to patients, nor achieved
any important reductions, as expected, due to their rela-
tively low level and exclusion of large parts of the popula-
tion. A higher rate of co-payment or »administrative
tax«, from 2005, resulted with the increased number of
population accessing complementary health insurance
(apart from compulsory insurance, conveyed by the CHIF),
which covered all categories of health service, including
drugs22. The largest proportion of complementary health
insurance users were usually high health service con-
sumers, older people and pensioners.
Several studies on pharmaceutical spending were pu-
blished in Croatia, with considerable diversity in scope
and time frame23–25, while the CHIF produced mostly ad-
ministrative reports on activity and financial turnover,
without applying the ATC DDD methodology of drug
consumption26,27. This study was, therefore, undertaken
with the aim of analyzing trends in quantity of issued
prescriptions and structure of prescribing in regard to
number of prescriptions per inhabitants and per patients
anually visiting PHC, from 2000 to 2012, based on the
CHIF data. Secondary objective was to estimate the pos-
sible impact of health care reforms implemented in con-
trol of pharmaceutical expenditure.
Methods
This is observational longitudinal investigation, ba-
sed on publicly available, routinelly collected data. The
main source of information were Reports on activity of
the Croatian Health Insurance Fund, and Reports on
finacial turnover of the CHIF, from 2002 to 201226,27.
Data on annual number of insured persons, number of
health care consumers, issued prescriptions (without
hospital care, and over-the-counter segment), and finan-
cial spending on prescription drugs were available from
the Reports.
Number of insured persons, together with rates of
prescriptions per insured person could be approximated
to the entire Croatian population because of the univer-
sal health insurance coverage by the state-owned CHIF
(a combination of Beverage and Bismark model). The in-
sured persons will, therefore, be considered simply as in-
habitants. The primary health care consumers (visiting
persons) will be named as patients. From the basic data,
the annual average number of prescriptions per inhabit-
ant and per patient, annual average financial expenses
per inhabitant and per patient, as well as differences in
these rates between regional CHIF offices situated in 20
Croatian counties, were calculated. Information on ad-
ministrative measures introduced for containment of
drug spending and other aspects of control were taken
from contracts between primary care physicians and the
CHIF, and checked subsequently and updated from the
administrative paper Narodne Novine.
The data were analysed using the Microsoft Office
(Excel and Access) software. Results are presented in ab-
solute numbers, frequency rates and graphically, and
trends are displayed as line charts.
Results
The total number of issued prescriptions was
29,213.229 in 2000, and 52,943.026 in 2012; 23,729.797
prescriptions or 81.2% more than in the first year. At the
same time, variations in the number of patients anually
visiting PHC were less than 10% (Figure 1).
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The rates of prescriptions per patient and per inhabit-
ant also increased, in proportion to the number of issued
prescriptions. Prescriptions per patient rised from 9.9 in
2000 to 16.4 in 2012 (increase of 6.5 prescriptions/pa-
tient, or 65%), while the number of prescriptions per in-
habitant rised from 6.98 in 2000 to 12.2 in 2012 (5.2 pre-
scriptions/inhabitant or 74%). The average annual per
capita prescription rate in Croatia (in all age groups, out-
patient segment) was approximately 12.4 prescriptions
per inhabitant (Figure 2).
Financial expenditure on prescription medicines rised
from 1.9 billions of HRK in 2000 to 3.03 billions in 2012,
or 71%. There was a relativelly rapid reaching of a pla-
teau in the last decade, of around 3.2 billions of HRK in
2004, which stayed unchanged until present, with a
slight decrease of 14.6% in 2010 (Figure 3).
Average financial spending per patient increased from
655.5 HRK in 2000 (85.6 EUR according to exchange
rate from 16.06.2014) to 1023.9 HRK (135.2 EUR) or
56.2%, while spending per inhabitant rised from 461.4
HRK (60.9 EUR) in 2000 to 758.2 HRK (100.1 EUR) in
2012, or 63.5%. Average financial expenditure per pa-
tient and per inhabitant increased until 2006, remaining
stable until now, except for a decrease of 12% in 2010
(Figure 4).
Regional offices of CHIF situated in county capitals
recorded greater number of prescriptions, with the larg-
est share of recipies in the City of Zagreb and Zagreba-
~ka-county (24.9% of the total number of items), as the
greatest and most populated urban area (1.1 million in-
habitants or 25.8% of the total population in 2011). The
number of issued prescriptions was, therefore, directly
correlated with the number of inhabitants in certain
area (Figure 5).
The growth of prescription volume in larger counties
oscillated moderatelly between 61 % (Split), 68.8% (Osi-
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Fig. 1. Number of issued prescriptions and patients receiving
primary care in Croatia, 2000–2012.
Fig. 2. Trends in the number of issued prescriptions per patient
visiting primary care and per inhabitant, in Croatia, 2000–2012.
Fig. 3. Overall financial expenditure on prescribed medicines in
Croatia, 2000–2012.
Fig. 4. Trends in financial expenditure on prescribed medicines
per patient and per inhabitant, in Croatia, 2000–2012.
Fig. 5. Trends in total number of prescriptions between CHIF re-
gional offices, in Croatia, 2000, 2006 and 2012.
jek), and 77% (Zagreb) while in smaller counties varied
greatly. The lowest rise was in Primorsko-goranska coun-
ty, centre Rijeka (24.8%), the highest in [ibensko-knin-
ska county, centre [ibenik (183.5%), and Me|imurska-
-county, centre ^akovec (167%) (Figure 6).
Number of prescriptions per capita (per inhabitant)
between counties fluctuated in 2002 more than in 2012.
Primorsko-goranska county (centre Rijeka) recorded 10.2
prescriptions/inhabitant (the uppermost value), while in
Li~ko-senjska (centre Gospi}), it was only 4.5 prescrip-
tions/inhabitant. The rates in 2012 became more equal,
but generally at higher level comparing with the previous
decade. That year Krapinsko-zagorska county (centre
Krapina) was leading with 13.8 prescriptions/inhabitant,
against 11.2 prescriptions/inhabitant in Splitsko-dalma-
tinska county (centre Split). The difference between the
two was, therefore, only 2.6 prescriptions/inhabitant,
against 5.7 prescriptions/inhabitant in 2002. Average an-
nual prescription per inhabitant for the entire Croatia
grew from 6.6 in 2002 to 12.4 in 2012; a difference of 5.7
prescriptions per capita or 86.6% (Figure 7).
Average annual expenses of prescriptions per capita
between counties in 2012 reflected similar trends as in
the total volume of recipies: the highest expenditure was,
again, in Krapinsko-zagorska county, with 861 HRK/pre-
scription/inhabitant (113.8 EUR), the lowest in Splitsko-
-dalmatinska county, with 701.3 HRK/prescription/in-
habitant (92.7 EUR), making a difference of 159.7 HRK/
prescription/inhabitant (21.1 EUR). The average cost of
individual prescription in 2012 was 62.4 HRK/prescrip-
tion/inhabitant (8.3 EUR) (Figure 8).
Discussion
The obtained results clearly indicate two trends:
firstly a rise of the quantity of issued prescriptions, to-
gether with accompanying rates of prescriptions per in-
habitant, and per patient, and secondly an increase in
the total cost of prescriptions until 2004, with some vari-
ations afterwards. The overall tendencies proved that
only measures towards regulation of drug prices had cer-
tain influence on drug spending while admininstrative
measures aimed at restraining of PHC physician's pre-
scribing volume and patients’ co-payment, were clearly
inadequate. Furthermore, the financial costs per inhabit-
ant – 758.2 HRK (100.1 EUR) in 2012, overcome the lim-
its of 680 HRK (90 EUR), set by the CHIF for the con-
tractual year 2012. As the quantity of recipies almost
doubled during the twelve year period, the number of pa-
tients visiting PHC remained relatively stable. The rise
in total volume of recipies together with accompanied
rates per patients under care, and per inhabitants fol-
lowed similar tendencies in other countries. Average an-
nual number of prescriptions per head of population was
12.4 in Croatia (2012), 12.9 in the USA (2010), 7.3 in It-
aly (2010), 8.57 in Germany (2012, prescription-only),
18.7 in the United Kingdom (2012, community pharma-
cies + general practices)28–31. Because of different meth-
odology of measurement of pharmaceutical consump-
tion, direct comparisons between countries are difficult
to perform.
Restrictions directed to PHC doctors, from average
annual number of prescriptions per persons on the list,
through punishing attempts in 2003, and financial limits
on prescription medicines in 1998, 2003 and 2005, were
@. Vojvodi} et al.: Trends in Prescribing Quantity and Pharmaceutical Spending, Coll. Antropol. 38 (2014) Suppl. 2: 67–72
70
Fig. 6. Growth of prescriptions issued in 2000 and 2012 between
CHIF regional offices in Croatia.
Fig. 7. Trends in prescription per inhabitant rates between Cro-
atian counties, in 2002 and 2012.
Fig. 8. Annual financial expenses per prescription per inhabit-
ant, between Croatian counties, in 2012.
therefore, unsuccesful in containing both trends15–21.
The efforts oriented toward restraining of PHC doctors
should, therefore, be re-directed toward improvement of
rational prescribing through the programs of continuing
professional development. Regional differences in the to-
tal volume of medicines consumed between the Croatian
counties are proportional with the number of inhabit-
ants, while the rates of increase and the number of pre-
scriptions per capita showed dissimilarities that could
not be explained with the results of this study. Further
research, aimed at analyzing interregional patients' of-
fice visits, number of patients that begun new chronic
therapy or morbidity patterns would probably shed more
light to this problem and at least partially explain differ-
ences. The overall financial expenditure increased too,
but stabilized after 2004, to around 3 billions of HRK.
Comparing the increase in volume of recipes with the
balanced levels of financial spending, it is understand-
able that not only the average cost per prescription de-
creased in the last several years, but the average cost of
drugs dropped as well. This was, probably, the result of
efficient negotiating between the CHIF and pharmaceu-
tical industry, aimed at lowering of drug prices, and
favorizing generics on the basic drug list.
Holding the prescription costs into check from the
year 2004, and their maintenance since then, indicate
that the CHIF quickly recognized the correctness of
turning measures towards pharmaceutical industry and
distibuteurs. It became clear, in a relatively short period
of time, that the future strategies in management of ex-
panding health care prices stand in that domaine, and
that restrictions in the side of demands (patients, pre-
scribers), although important, are not as substantial as
those on the side of offers.
This study is, until now, the first in Croatia investi-
gating time-line trends of the quantity and regional dis-
tribution of prescription items. Additional strenghts are
in the use of official data (CHIF annual reports), which
are utilized for health system organizational planning,
too. The reliability of data and their decade-long continu-
ity in the Reports, allowed for determination of trends.
The fact that the same data which made possible the con-
struction of trends, were insufficient for deeper analysis
of structure of drug use in the population, limits to some
degree the applicability of results. Despite limitations,
results of this investigation could potentially assist deci-
sion makers in further employment of efficient tools in
controlling the drug costs, such are negotitations with
pharmaceutical industry, and substitution of brand prod-
ucts with generics.
Conclusion
Both the total prescription volume and the cost of pre-
scriptions expanded rapidly in Croatia from the year
2000, despite insignificant changes in demographic indi-
cators. Costs of prescribed medications, however, stabi-
lised from 2004, most probable because of negotiating of
drug prices, maintaining strict rules on inclusion of new
medicines on the basic drug list and introducing of gene-
rics. In contrast, the number of prescriptions issued by
the PHC physicians rapidly accelerated in spite of restri-
cive measures imposed from CHIF to moderate finacial
expenses. This study only demonstrated trends, there-
fore the future research detailing the structure of thera-
peutic consumption together with employment of indica-
tors of medication appropriateness would probably
explain factors influencing pharmaceutical volume and
costs, as well as patterns od drug utilization in Croatia.
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TRENDOVI KRETANJA IZDAVANJA RECEPATA I FARMACEUTSKE POTRO[NJE U HRVATSKOJ:
OPSERVACIJSKA STUDIJA NA TEMELJU RUTINSKI PRIKUPLJENIH PODATAKA OD 2000–2012
S A @ E T A K
Rast farmaceutskih tro{kova zna~ajno optere}uje sveukupnu zdravstvenu potro{nju. Hrvatski Zavod za Zdravstve-
no Osiguranje, poku{avaju}i ograni~iti tro{kove, koristi administrativne mjere usmjerene ka dvama najve}im potro{a-
~ima: farmaceutskoj industriji, putem pregovaranja o cijenama lijekova i periodi~nim revizijama osnovne i dopunske
liste lijekova, te lije~nicima primarne zdravstvene za{tite, putem ograni~avanja najve}eg broja recepata koji se mogu
prepisati tijekom jedne godine te njihove financijske potro{nje. Cilj je ove studije utvr|ivanje kretanja koli~ine izdanih
recepata te farmaceutske potro{nje, od 2000 do 2012. Podatci su preuzeti iz godi{njih izvje{taja HZZO. Rezultati jasno
pokazuju dva trenda: porast koli~ine izdanih recepata, zajedno s prate}im stopama broja recepata po stanovniku i po
pacijentu, te porast tro{kova lijekova izdanih na recept do 2006. godine te njihovo odr`avanje uz neznatne varijacije, do
danas. Unato~ kontroverzama u pristupu, HZZO je uspje{no usporio rast tro{kova, u prvom redu primjenom mjera
usmjerenih ka regulaciji cijena lijekova.
@. Vojvodi} et al.: Trends in Prescribing Quantity and Pharmaceutical Spending, Coll. Antropol. 38 (2014) Suppl. 2: 67–72
72
